PL3337829T3 - Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE) - Google Patents

Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE)

Info

Publication number
PL3337829T3
PL3337829T3 PL17708098T PL17708098T PL3337829T3 PL 3337829 T3 PL3337829 T3 PL 3337829T3 PL 17708098 T PL17708098 T PL 17708098T PL 17708098 T PL17708098 T PL 17708098T PL 3337829 T3 PL3337829 T3 PL 3337829T3
Authority
PL
Poland
Prior art keywords
cancer
antibody
age
composition
end products
Prior art date
Application number
PL17708098T
Other languages
English (en)
Inventor
Lewis S. Gruber
Original Assignee
Siwa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corporation filed Critical Siwa Corporation
Publication of PL3337829T3 publication Critical patent/PL3337829T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17708098T 2016-02-19 2017-02-16 Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE) PL3337829T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662297744P 2016-02-19 2016-02-19
US201662425495P 2016-11-22 2016-11-22
EP17708098.3A EP3337829B1 (en) 2016-02-19 2017-02-16 Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
PCT/US2017/018185 WO2017143073A1 (en) 2016-02-19 2017-02-16 Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)

Publications (1)

Publication Number Publication Date
PL3337829T3 true PL3337829T3 (pl) 2020-05-18

Family

ID=58191665

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17708098T PL3337829T3 (pl) 2016-02-19 2017-02-16 Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE)

Country Status (16)

Country Link
US (1) US11833202B2 (pl)
EP (3) EP4067386A1 (pl)
JP (2) JP6722293B2 (pl)
KR (2) KR102786111B1 (pl)
CN (1) CN109071675A (pl)
AU (1) AU2017219749B2 (pl)
CA (1) CA3021150C (pl)
DK (2) DK3677598T3 (pl)
ES (2) ES2770787T3 (pl)
HU (2) HUE058854T2 (pl)
IL (2) IL283726B2 (pl)
MX (2) MX2018009988A (pl)
PL (1) PL3337829T3 (pl)
PT (1) PT3337829T (pl)
RU (1) RU2728964C2 (pl)
WO (1) WO2017143073A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987416A (zh) 2008-05-23 2015-10-21 Siwa有限公司 促进再生的方法、组合物及设备
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
RU2721568C2 (ru) 2014-09-19 2020-05-20 Сива Корпорейшн Анти-age антитела для лечения воспаления и аутоиммунных нарушений
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
AU2017219749B2 (en) 2016-02-19 2022-01-06 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CA3062082A1 (en) 2017-05-04 2018-11-08 Siwa Corporation Diagnostic advanced glycation end-product antibodies
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US20220175916A1 (en) * 2018-07-23 2022-06-09 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
JP2021534144A (ja) 2018-08-23 2021-12-09 シワ コーポレーション Ａｇｅ修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波
CA3177449A1 (en) * 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US5811075A (en) 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US4900747A (en) 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
JP2644767B2 (ja) 1986-09-12 1997-08-25 ザ ロックフェラー ユニバーシティ 後生的なグリコシル化最終産物を除去する為の方法及び薬剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040208826A1 (en) 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (pl) 1990-04-02 1993-05-01 Sint Sa
US20080063603A1 (en) 1990-04-02 2008-03-13 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5601526A (en) 1991-12-20 1997-02-11 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
WO1994000592A1 (en) 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5620479A (en) 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5518720A (en) 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5744300A (en) 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
EP0753071A1 (en) 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5935927A (en) 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5744318A (en) 1994-12-30 1998-04-28 Alteon Inc. Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples
ATE245169T1 (de) 1994-12-30 2003-08-15 Alteon Inc Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
AU6907496A (en) 1995-08-25 1997-03-19 Case Western Reserve University Process for detecting pentosidine and for assessing the biological age of a biological sample
US5620409A (en) 1995-09-15 1997-04-15 The Research Foundation Of State University Of New York Method for inhibiting clot formation
JP3579549B2 (ja) 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5664570A (en) 1996-02-20 1997-09-09 Svc Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
WO2000020621A1 (en) 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
CN1270637A (zh) 1997-08-08 2000-10-18 华盛顿大学 新的衰老因子基因p23的分离
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6896659B2 (en) 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
JP4016304B2 (ja) 1998-02-26 2007-12-05 日本油脂株式会社 モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法
JP2002517224A (ja) 1998-06-09 2002-06-18 アルテオン インコーポレーテッド 生体サンプル内におけるグアニジノ基由来進行グリコシル化最終生成物に特異的なモノクローナル抗体
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
US6309355B1 (en) 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
DE60045240D1 (de) 1999-03-02 2010-12-30 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
US6067859A (en) 1999-03-04 2000-05-30 The Board Of Regents, The University Of Texas System Optical stretcher
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
CA2382095A1 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
WO2001018060A1 (fr) 1999-09-08 2001-03-15 Toray Industries, Inc. Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique
US6853864B2 (en) 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
EP1283728A2 (en) 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
NO312338B1 (no) 2000-08-25 2002-04-29 Gunnar Myhr Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN2445326Y (zh) 2000-10-09 2001-08-29 刘永详 测定被糖化蛋白的免疫分析装置
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7481781B2 (en) 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
US7347855B2 (en) 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
AU2002217412B2 (en) 2001-01-03 2006-09-14 Ultrashape Ltd. Non-invasive ultrasonic body contouring
DE60202008T2 (de) 2001-03-22 2005-12-01 Roche Diagnostics Gmbh Verfahren zum Auffinden von Reagenzien und Festphasenkomponenten in spezifischen Bindungsassays, frei von fortgeschrittenen Glykosylierungsendprodukten
EP1415997A4 (en) * 2001-07-19 2005-03-30 Mitsubishi Pharma Corp POLYPEPTIDES THAT PLAY A ROLE IN THE SIGNAL TRANSMISSION OF THE ADVANCED GLYCATION END PRODUCT RECEPTOR
JP4012722B2 (ja) 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
ES2385378T3 (es) 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
BR0313491A (pt) 2002-08-16 2007-08-14 Wyeth Corp composições e métodos para tratar distúrbios associados ao rage
US20070128117A1 (en) 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP1601969A2 (en) 2003-03-08 2005-12-07 Auvation Ltd Markers for colorectal cancer
WO2005009256A2 (de) 2003-07-31 2005-02-03 Woodwelding Ag Verfahren und vorrichtung zur förderung der geweberegeneration an wundflächen
US7358226B2 (en) 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
CA2554239C (en) 2004-01-20 2015-05-12 Sunnybrook And Women's College Health Sciences Centre High frequency ultrasound imaging using contrast agents
MXPA06009363A (es) 2004-02-17 2007-01-26 Dynamis Therapeutics Inc Fructosaamina 3 cinasa y la formacion de colageno y elastina.
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1866663A1 (en) 2005-03-03 2007-12-19 Bracco Research S.A. Medical imaging system based on a targeted contrast agent
JP2006249015A (ja) 2005-03-11 2006-09-21 Mochida Pharmaceut Co Ltd 細胞老化抑制剤
EP1867659A4 (en) 2005-04-05 2008-12-31 Jms Co Ltd SPECIAL ANTIBODY AGAINST 3,4-DGE DERIVED AGE
JP2006288864A (ja) 2005-04-13 2006-10-26 Padoru:Kk 外科手術用の骨固定具
US20070225242A1 (en) 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007027584A2 (en) 2005-08-30 2007-03-08 University Of Virginia Patent Foundation Deposit contrast agents and related methods thereof
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en) 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy
US20070078290A1 (en) 2005-09-30 2007-04-05 Esenaliev Rinat O Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues
US7766833B2 (en) 2005-11-23 2010-08-03 General Electric Company Ablation array having independently activated ablation elements
JP4779115B2 (ja) * 2005-12-16 2011-09-28 国立大学法人東北大学 早期肺癌の術後予後検査方法
WO2007098186A2 (en) 2006-02-22 2007-08-30 Novavax, Inc. Adjuvant and vaccine compositions
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
WO2008154638A2 (en) * 2007-06-12 2008-12-18 Board Of Regents, The University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
MX2009013194A (es) 2007-06-14 2010-03-30 Galactica Pharmaceuticals Inc Proteinas de fusion del receptor para productos finales de glicacion avanzada.
JP2007277263A (ja) 2007-07-13 2007-10-25 Transgenic Inc カルボキシメチル化タンパク質に対する抗体
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US7751057B2 (en) 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
DE102008009461A1 (de) 2008-02-15 2009-08-20 Beiersdorf Ag Verfahren zur Reduzierung der Zeichen der Hautalterung
KR101649189B1 (ko) * 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
CN104987416A (zh) 2008-05-23 2015-10-21 Siwa有限公司 促进再生的方法、组合物及设备
JP5229473B2 (ja) 2008-06-04 2013-07-03 財団法人ヒューマンサイエンス振興財団 超音波医療装置
US20110319499A1 (en) 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
EP2399934B1 (en) 2009-02-20 2017-09-06 The University of Tokyo Novel monoclonal antibody, and use thereof
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011035104A1 (en) 2009-09-17 2011-03-24 Sanuwave, Inc. Methods and devices for cleaning and sterilization with shock waves
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
WO2011053322A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011101039A1 (en) 2010-02-22 2011-08-25 Universite Pierre Et Marie Curie (Paris 6) Apparatus for the treatment of brain affections and method implementing thereof
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US9649376B2 (en) * 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2013009787A2 (en) 2011-07-10 2013-01-17 Guided Therapy Systems, Llc Methods and systems for ultrasound treatment
US8954155B2 (en) 2011-09-19 2015-02-10 Biotalk Technologies Inc Apparatus and method for rejuvenating skin
AU2012311428A1 (en) 2011-09-23 2014-04-24 Julius-Maximilians-Universitat Wurzburg Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
KR20140119023A (ko) 2011-12-13 2014-10-08 버크 인스티튜트 포 리서치 온 에이징 의료 요법을 개선하는 방법
BR112014019861A2 (pt) 2012-02-17 2017-07-04 Seattle Genetics Inc anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US20130288980A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent and cancer cells for selective killing by interference with foxo4
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
KR101520336B1 (ko) 2012-11-30 2015-05-14 전남대학교산학협력단 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
EP2742935A1 (en) 2012-12-14 2014-06-18 Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH SERF2 for the treatment of atrophy and for increasing cell growth
WO2014136113A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US20140257262A1 (en) 2013-03-11 2014-09-11 Alexandre Carpentier Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same
CA2902432A1 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
JP6549560B2 (ja) 2013-05-14 2019-07-24 上海 ハイチャーム インコーポレーテッドＳｈａｎｇｈａｉ Ｈｙｃｈａｒｍ Ｉｎｃ． 低免疫原性タンパク質に対するエピトープワクチンおよびその製造方法と使用
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
EP3094350B1 (en) 2014-01-15 2020-03-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cartilage targeting agents and their use
EP3096824A1 (en) 2014-01-24 2016-11-30 Cole Research&Design, Inc. Oral suction device
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
RU2721568C2 (ru) 2014-09-19 2020-05-20 Сива Корпорейшн Анти-age антитела для лечения воспаления и аутоиммунных нарушений
EP3207062A1 (en) * 2014-10-16 2017-08-23 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
AU2016336959A1 (en) 2015-10-13 2018-04-12 Siwa Corporation Anti-age antibodies and methods of use thereof
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
AU2017219749B2 (en) 2016-02-19 2022-01-06 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US10981021B2 (en) 2016-03-11 2021-04-20 Carthera Method for transiently disrupting a region of the blood-brain barrier of a human
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US10172684B2 (en) 2016-04-29 2019-01-08 Ethicon Llc Lifecycle monitoring features for surgical instrument
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
RU2617313C1 (ru) 2016-07-18 2017-04-24 Государственное автономное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Институт медицинских клеточных технологий" Способ определения биологического возраста у мужчин
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CA3062082A1 (en) 2017-05-04 2018-11-08 Siwa Corporation Diagnostic advanced glycation end-product antibodies
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US20220175916A1 (en) 2018-07-23 2022-06-09 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
CN112888788A (zh) 2018-08-14 2021-06-01 艾梅尔生物治疗公司 用于治疗线粒体疾病或病症和异质性的方法和组合物
JP2021534144A (ja) 2018-08-23 2021-12-09 シワ コーポレーション Ａｇｅ修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波
CA3177449A1 (en) 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
WO2021247397A2 (en) 2020-06-04 2021-12-09 Siwa Corporation Methods and compositions for enhancing the immune system
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
WO2023177390A1 (en) 2022-03-14 2023-09-21 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer

Also Published As

Publication number Publication date
RU2018132998A3 (pl) 2020-05-29
RU2018132998A (ru) 2020-03-19
JP6722293B2 (ja) 2020-07-15
WO2017143073A1 (en) 2017-08-24
EP3677598A1 (en) 2020-07-08
KR102786111B1 (ko) 2025-03-26
KR20180110090A (ko) 2018-10-08
MX2022014630A (es) 2023-02-23
KR102536017B1 (ko) 2023-05-24
DK3677598T3 (da) 2022-05-30
EP3337829A1 (en) 2018-06-27
IL261006B (en) 2021-06-30
MX2018009988A (es) 2018-12-17
US11833202B2 (en) 2023-12-05
CA3021150A1 (en) 2017-08-24
KR20230074837A (ko) 2023-05-31
IL283726B2 (en) 2025-05-01
PT3337829T (pt) 2020-02-10
ES2770787T3 (es) 2020-07-03
CN109071675A (zh) 2018-12-21
CA3021150C (en) 2023-02-07
IL283726A (en) 2021-07-29
DK3337829T3 (da) 2020-02-17
RU2728964C2 (ru) 2020-08-03
AU2017219749A1 (en) 2018-08-23
ES2912064T3 (es) 2022-05-24
IL283726B1 (en) 2025-01-01
JP2019511469A (ja) 2019-04-25
HUE047922T2 (hu) 2020-05-28
EP3677598B1 (en) 2022-04-06
US20190031781A1 (en) 2019-01-31
JP2020158531A (ja) 2020-10-01
EP4067386A1 (en) 2022-10-05
HUE058854T2 (hu) 2022-09-28
HK1256931A1 (en) 2019-10-04
IL261006A (en) 2018-10-31
JP6811887B2 (ja) 2021-01-13
EP3337829B1 (en) 2020-01-08
AU2017219749B2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
PL3337829T3 (pl) Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE)
PL3283435T3 (pl) Kompozycja, materiały cząsteczkowe i sposoby wytwarzania materiałów cząsteczkowych
IL255884A (en) Modified nk-92 cells for cancer treatment
EP3355643A4 (en) Method for processing channel collisions in direct mode operation mode, and terminal
ZA201802700B (en) Foam modifiers for cementitious slurries, methods, and products
EP3033091A4 (en) Method and compositions for treating cancer using probiotics cross-reference to related application
IL258980A (en) Preparation of bispecific antigens and their use in cancer
EP3156037A4 (en) Alpha-gel-intermediate composition, and production method for alpha-gel-containing o/w emulsion cosmetic using said composition
IL248766A0 (en) A method for treating renal cell cancer
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EP3156043A4 (en) A-gel-intermediate composition, and production method for a-gel-containing o/w emulsion cosmetic using said composition
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
ZA201507688B (en) Method, apparatus, and computer-readable medium for advancing prepaid credit
SI3095722T1 (sl) Embalaža za živila, zlasti za prigrizke, ter postopek za izdelavo le-te
GB201412213D0 (en) Material,composition and method
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
PL3307065T3 (pl) Komórki chimeryczne związane z dystrofią mięśniową i sposób leczenia dystrofii mięśniowych
PT3245032T (pt) Aparelho e método para cortar produtos
EP3273970A4 (en) Methods and materials for treating cancer
GB201307091D0 (en) Composition, Apparatus and Method for Treating Waste Products
EP3199152A4 (en) Anti-cancer agent and method for killing cancer cells
SG11201604454QA (en) Composition, method for preparing sugar chain sample, and method for analyzing sugar chain
HUE060565T2 (hu) Frukto-oligoszacharidokat tartalmazó trágyázó és biostimuláló készítmény, kijuttatási eljárása és alkalmazása
EP3522925A4 (en) METHOD FOR TREATING CANCER METASTASES AND COMPOSITION THEREOF